| Clinical data | |
|---|---|
| Trade names | Barnetil, Barnotil, Topral |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral,IM |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Eliminationhalf-life | 3–5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.053.293 |
| Chemical and physical data | |
| Formula | C17H26N2O4S |
| Molar mass | 354.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Sultopride (trade namesBarnetil,Barnotil,Topral) is anatypical antipsychotic of thebenzamidechemical class used inEurope,Japan, andHong Kong for the treatment ofschizophrenia.[2][3][4] It was launched bySanofi-Aventis in 1976.[2] Sultopride acts as aselectiveD2 andD3 receptorantagonist.[5] It has also been shown to have clinically relevantaffinity for theGHB receptor as well, a property it shares in common withamisulpride andsulpiride.[6]
| Site | Ki | Species | Ref |
|---|---|---|---|
| D2 | 1.6 | Human | [7] |
| D3 | 3.8 | Human | [7] |
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |